Total Investment of Approx. USD 11.6 Million in TB and NTD R&D Projects With Partners Including Fujifilm, Stop TB Partnership, and the Ohio State University
TOKYO, Oct. 29, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.73 billion (USD 11.6 million1) in four R&D projects for the development of diagnostics and a...
Tencent's CarbonX Program 2.0 Identifies 50 Global Finalists in Race to Scale Climate Solutions
SHENZHEN, China, Oct. 29, 2025 /PRNewswire/ -- Tencent (0700.HK) today announced the top 50 finalists, coming from 12 countries and regions around the world, for its CarbonX Program 2.0 (CarbonX 2.0), a landmark initiative to accelerate next...
Work Programs Commence to Unlock Tantalum as a High-Value By-Product Critical Metal Opportunity
Shaakichiuwaanaan rapidly evolving into an emerging critical minerals powerhouse, with workstreams now underway on caesium, tantalum, and gallium opportunities MONTREAL, June 25, 2025 /PRNewswire/ -- June 26, 2025 – Sydney, Australia Highlights...
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN). Findings...
UBTS and Cuber AI Launch Exploratory Study into Next-Gen Agentic AI for Logistics Innovation
Joint initiative to evaluate Agentic AI-driven transformation of supply chain operations across ASEAN SINGAPORE, May 30, 2025 /PRNewswire/ -- UBTS Pte Ltd, a leading Singapore homegrown logistics player, has embarked on an exploratory partnership...
NYSE Content Advisory: Pre-Market update + Hinge Health, MNTN pop double digits in trading debuts
NEW YORK, May 23, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scholer...
Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual Meeting
Preliminary efficacy analysis from the elacestrant plus everolimus and ribociclib cohorts of the ELEVATE study, along with updated safety data from additional cohorts of elacestrant plus targeted therapy combination arms, will be presented. These...
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)
- ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy. SHANGHAI and HONG KONG, May 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative,...
Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity
- The combination study is designed to evaluate the safety and preliminary efficacy of a single-dose of ultra-long-acting subcutaneously administered ASC47 in combination with four doses of semaglutide (0.5 mg, once-weekly) in participants with...
Global Times: Exclusive interview with renowned Chinese sculptor and NAMOC Director Wu Weishan
BEIJING, May 19, 2025 /PRNewswire/ -- In recent years, Chinese culture has been blooming in all its diversity, continuously achieving remarkable success overseas. In this Cultural Outreach Talk series, the Global Times invites insiders from...